

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (currently amended) A factor X analog which contains a modification between Glu226 and Ile235 of SEQ ID NO:2, relative to the amino acid numbering according to Figure 1, such that amino acids Glu226 to Arg234 and residue 235 of SEQ ID NO:2 have the sequence Glu226-R8-R7-R6-R5-R4-R3-R2-Arg234-R1, wherein

- a) R1 is Ile, Val, or Ala;
- b) R2 is Thr, Ser, or Asn;
- c) R3 is Phe, Leu, Arg, or Ile;
- d) R4 is ~~Asp~~, Asp, Lys, Thr, or Glu;
- e) R5 is Asn, Ser, Lys, Met, Thr, or Asp;
- f) R6 is Phe, Thr, Ser, Pro, Leu, or Ile;
- g) R7 is Ser, Gln, Ile, Thr, Asn, or Pro; and
- h) R8 is Gln, Ser, His, Tyr, or Glu.

2-3. (canceled)

4. (currently amended) The factor X analog of claim 1, wherein ~~characterized in that it contains a modification in the region of amino acids~~ the amino acid sequence of residues 227-233 (R8-R7-R6-R5-R4-R3-R2) of the factor X sequence, relative to the amino acid numbering according to Figure 1, as follows: is  
Gln227-Ser228-Phe229-Asn230-Asp231-Phe232- Thr233 (SEQ ID NO:17).~~Thr233~~

5. (currently amended) The factor X analog of ~~claim 4~~ claim 4, wherein amino acid 235 is also modified.

6. (currently amended) The factor X analog of claim 1, wherein ~~characterized in that it contains a modification in the region of amino acids~~ the amino acid

sequence from residues 227-233 (R8-R7-R6-R5-R4-R3-R2) of the factor X sequence, relative to the amino acid numbering according to Figure 1, as follows: is Ser 227-Gln228-Thr229-Ser230-Lys231-Leu232 (SEQ ID NO:18). Ser227-Gln228-Thr229-Ser230-Lys231-Leu232-Thr233.

7. (currently amended) The factor X analog of ~~claim 6~~ claim 6, wherein amino acid 235 is also modified.
8. (currently amended) The factor X analog of ~~claim 1~~ claim 1, wherein the modification forms a processing site for factor XIa or a derivative thereof.
9. (currently amended) The factor X analog of ~~claim 1~~ claim 1, ~~characterized in that it has~~ further comprising an additional modification in the region of the C-terminal factor X amino acid sequence.
10. (currently amended) The factor X analog of as claimed in Claim ~~claim 9,~~ characterized in that it has wherein the additional modification is a modification in the C-terminal region of the  $\beta$ -peptide cleavage site.
11. (currently amended) The factor X analog of ~~claim 1~~ claim 1, wherein said modification permits an *in vivo* activation of the factor X analog into native factor Xa or a factor Xa analog.
12. (currently amended) The factor X analog of ~~claim 1~~ claim 1, wherein said modification permits an *in vitro* activation of the factor X analog into native factor Xa or a factor Xa analog.
13. (currently amended) The factor X analog of ~~claim 1~~ claim 1, wherein said analog contains an intact  $\beta$ -peptide.
14. (currently amended) The factor X analog of claim 1 which is in the form of a double-chain molecule.

15. (original) The factor X analog of claim 1 having a shortened C-terminal region.

16. (canceled).

17. (currently amended) A preparation ~~containing a purified~~ comprising the factor X analog of claim 1 or a precursor protein thereof, ~~said factor X analog containing a modification between Glu226 and Ile235, relative to the amino acid numbering according to Figure 1.~~

18. (currently amended) The preparation of ~~claim 17~~ claim 17, wherein the modification is between Glu226 and Arg234 of SEQ ID NO:2.

19. (currently amended) The preparation as claimed in ~~Claim~~ of claim 17, ~~characterized in that~~ wherein the modification forms a cleavage site for factor XIa or a derivative thereof.

20. (currently amended) The preparation of claim 17, ~~characterized in that~~ wherein the factor X analog is ~~present in the form of a~~ FX $\alpha$  analog.

21. (currently amended) The preparation of ~~claim 17~~ claim 17, wherein the factor X analog has a shortened C-terminal amino acid sequence.

22. (currently amended) The preparation of claim 17, ~~characterized in that it contains~~ wherein the factor X analog is a double-chain molecule.

23. (currently amended) The preparation of claim 17, ~~characterized in that it contains~~ wherein

the factor X analog is a single-chain factor X analog in enzymatically inactive form, with a purity of a minimum of that is at least 80% pure; and

the preparation ~~that it~~ does not contain inactive proteolytic intermediates of factor X/Xa analog.

24. (currently amended) The preparation of claim 17, ~~characterized in that it contains~~ wherein the factor X analog ~~as is~~ a single-chain molecule.

25. (currently amended) The preparation of claim 17, ~~characterized in that it contains a~~ wherein the factor X analog ~~which has a~~ modification ~~that~~ permits an *in vivo* activation of the factor X analog into native factor Xa or ~~into~~ a factor Xa analog.

26. (currently amended) The preparation of claim 17, ~~characterized in that it contains a~~ wherein the factor X analog ~~which has a~~ modification ~~that~~ permits an *in vitro* activation of the factor X analog into native factor Xa or into a factor Xa analog.

27. (currently amended) The preparation of claim 17, ~~characterized in that it~~ 17 that is formulated as a pharmaceutical preparation.

28. (currently amended) A method for obtaining a preparation comprising an activated factor X analog, the method comprising: ~~obtainable by activation of the factor X analog of claim 1, said activated factor X analog having high stability and structural integrity, said preparation being free from inactive factor X/Xa analog intermediates and autoproteolytic factor X decomposition products~~

- (a) providing the factor X analog of claim 1; and
- (b) activating the factor X analog to obtain the activated factor X analog.

29. (currently amended) The ~~preparation method~~ method of claim 28, ~~characterized in that it contains~~ further comprising formulating the preparation with a physiologically acceptable matrix ~~and is present in a form that is stable to storage.~~

30. (currently amended) The ~~preparation method~~ method of claim 28, ~~characterized in that it contains~~ further comprising combining the preparation with a blood factor or an activated form of a blood factor as an additional component.

31. (currently amended) The ~~preparation method~~ of claim 30, ~~characterized in that it contains a minimum of~~ wherein the additional component comprises at least one component with factor VIII inhibitory bypass activity ~~as an additional component~~.

32. (currently amended) The preparation of claim 17, ~~characterized in that it~~ that is formulated as a pharmaceutical compound and is present as a multi-component preparation.

33. (currently amended) ~~The use of the preparation of claim 17 to produce a drug.~~ A method for preparing a pharmaceutical composition, comprising formulating the preparation of claim 17 as pharmaceutical composition.

34 -43. (canceled)